GLP-1 agonists, such as liraglutide and semaglutide, are increasingly used in medical weight loss due to their ability to mimic the natural hormone glucagon-like peptide-1, which is, for the most part, responsible for regulating appetite and food intake
A 2022 review in the Journal of Clinical and Aesthetic Dermatology noted that dermatological adverse events, while relatively uncommon, represent an important consideration in GLP-1 agonist therapy
After making payment, we will ensure that a valid prescription is received from your prescriber
Consuming alcohol with or after a meal containing carbohydrates, protein, and fat helps moderate both alcohol absorption and blood glucose fluctuations
Our licensed providers offer free online evaluations, and if prescribed, your medication is shipped directly to your door
Outcomes Primary and Secondary Outcome Patients in the semaglutide study arm experienced a significantly lower rate of the primary outcome (cardiovascular composite end-point) (6.5% vs 8.0%, HR 0.80 (95% CI 0.72-0.90) No significant difference in rates of cardiac death (HR 0.85, 95% CI 0.71-1.01) however significantly lower rates of heart failure (HR 0.82, 95% CI 0.71-0.96) and all-cause mortality (HR 0.81, 95% CI 0.71-0.93) Adverse Events Rates and types of adverse events were fairly similar between control and intervention groups Permanent premature discontinuation of semaglutide or placebo occurred in 2351 patients (26.7%) in the semaglutide group and 2078 (23.6%) in the placebo group In obese and overweight patients with cardiovascular comorbidities but without diabetes, treatment with weekly semaglutide was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months
